Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) who have an EGFR mutation. However, little has been reported about the association between EGFR exon 19 deletions or an exon 21 mutation (specifically the L858R point mutation) and survival rates following first-line EGFR-TKI treatment in patients with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Diagnosis and Treatment
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations